• SPX
  • $5,751.07
  • 0.9 %
  • $51.13
  • DJI
  • $42,352.75
  • 0.81 %
  • $341.16
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,280.63
  • -0.02 %
  • -$1.89
  • IXIC
  • $18,137.85
  • 1.22 %
  • $219.38
Reviva Pharmaceuticals Holdings, Inc. (RVPHW) Stock Price, News & Analysis

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.09

-$0

(-3.15%)

Day's range
$0.09
Day's range
$0.11
50-day range
$0.0737
Day's range
$0.29
  • Country: US
  • ISIN: US76152G1186
52 wk range
$0.09
Day's range
$0.11
  • CEO: Dr. Laxminarayan Bhat Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -54.49
  • Piotroski Score 2.00
  • Grade N/A
  • Symbol (RVPHW)
  • Company Reviva Pharmaceuticals Holdings, Inc.
  • Price $0.09
  • Changes Percentage (-3.15%)
  • Change -$0
  • Day Low $0.09
  • Day High $0.11
  • Year High $0.11

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/30/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.00
  • Trailing P/E Ratio N/A
  • Forward P/E Ratio N/A
  • P/E Growth N/A
  • Net Income $-24,339,292

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.